Zobrazeno 1 - 10
of 564
pro vyhledávání: '"A Colowick"'
Autor:
Barnes, David W., Colowick, Sidney P.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 1977 Dec 01. 74(12), 5593-5597.
Externí odkaz:
https://www.jstor.org/stable/67404
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 1979 Oct 01. 76(10), 5080-5084.
Externí odkaz:
https://www.jstor.org/stable/70391
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 1985 Mar 01. 82(5), 1346-1349.
Externí odkaz:
https://www.jstor.org/stable/25405
Autor:
Colowick, Sidney P.
Publikováno v:
Science, 1958 Sep 01. 128(3323), 519-521.
Externí odkaz:
https://www.jstor.org/stable/1755814
Autor:
Kotasek, D., Steger, G., Faught, W., Underhill, C., Poulsen, E., Colowick, A.B., Rossi, G., Mackey, J.
Publikováno v:
In European Journal of Cancer September 2003 39(14):2026-2034
Publikováno v:
In Blood 1 September 2000 96(5):1698-1702
Publikováno v:
Cytokines Cellular & Molecular Therapy. Jun2002, Vol. 7 Issue 2, p49. 11p.
Publikováno v:
Haemophilia. Nov99, Vol. 5 Issue 6, p374. 4p. 1 Diagram.
Autor:
A B Colowick, N S Tchekmedyian, G. Rossi, Glen R. Justice, S Armstrong, J. Jadeja, J Kessler, J O'Byrne, John A. Glaspy, D Richards, Lee S. Schwartzberg
Publikováno v:
British Journal of Cancer
British journal of cancer, vol 87, iss 3
British journal of cancer, vol 87, iss 3
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg−1 wk−1 or to a control group receiving epoetin alfa at an initial dose of 150 U kg−1 three times weekly. In part B, the coh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a25a1cc10e213daf4707f1a43bc274dc
https://doi.org/10.1038/sj.bjc.6600465
https://doi.org/10.1038/sj.bjc.6600465
Autor:
Nancy E. Colowick, Heidi E. Hamm, Frank E. Harrell, Yanna Song, John H. Cleator, Willie J. Hudson, Matthew T. Duvernay, Michael Holinstat
Although resistance to the P2Y12 antagonist clopidogrel is linked to altered drug metabolism, some studies suggest that these pharmacokinetic abnormalities only partially account for drug resistance. To circumvent pharmacokinetic complications and ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a8f3ca238491df2ba1102d806d156bc
https://europepmc.org/articles/PMC4165026/
https://europepmc.org/articles/PMC4165026/
